N-Isopropyl-hexahydro-1,5-oxazocin | 61999-53-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-Isopropyl-hexahydro-1,5-oxazocin
• 英文别名: 5-isopropyl-[1,5]oxazocane；2H-1,5-Oxazocine, hexahydro-5-(1-methylethyl)-；5-propan-2-yl-1,5-oxazocane
• CAS: 61999-53-9
• 化学式: C₉H₁₉NO
• 分子量: 157.256
• InChiKey: OTKAGYJHXWHIGK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1,7-二氯-4-氧杂庚烷 、 异丙胺 以25%的产率得到
  参考文献：
  名称：

  GLINKA R.; KOTELKO B., ACTA POL. PHARM. , 1976, NO 1, 33, 39-48

  摘要：

  DOI：

文献信息

• DIPHENYL DERIVATIVES AND USES THEREOF
  申请人：NOVARTIS AG

  公开号：US20190077773A1

  公开（公告）日：2019-03-14

  The present disclosure provides a compound of formula (I): or a pharmaceutically acceptable salt thereof, and its therapeutic uses for activating a growth factor pathway, promoting wound healing, promoting tissue repair, and treating hearing loss, skeletal muscle loss, organ degeneration, tissue damage, neurodegeneration, and muscular atrophy. The disclosure further provides pharmaceutical compositions and combinations. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.

  本公开提供了一种公式(I)的化合物： 或其药用可接受的盐，以及其用于激活生长因子途径、促进伤口愈合、促进组织修复以及治疗听力损失、骨骼肌损失、器官退化、组织损伤、神经退化和肌肉萎缩的治疗用途。本公开还提供了药物组合物和组合物。本公开还涉及将此类化合物用于研究或其他非治疗目的。
• AZOCANE AND AZONANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS
  申请人：Novira Therapeutics, Inc.

  公开号：US20160272599A1

  公开（公告）日：2016-09-22

  Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

  本文提供了一些对需要治疗HBV感染的患者有用的化合物，它们的药物组合物，以及抑制、抑制或预防患者HBV感染的方法。
• [EN] PROCESS FOR PREPARING GUANIDINO-FUNCTIONAL MONOMERS<br/>[FR] PROCÉDÉ POUR LA PRÉPARATION DE MONOMÈRES À FONCTION GUANIDINO
  申请人：3M INNOVATIVE PROPERTIES CO

  公开号：WO2014204763A1

  公开（公告）日：2014-12-24

  A process for preparing guanidino-functional, free radically polymerizable compounds comprises (a) combining (1) an amine compound comprising (i) at least one primary aliphatic amino group and (ii) at least one secondary aliphatic amino group, primary aromatic amino group, or secondary aromatic amino group, and (2) a guanylating agent; (b) allowing or inducing reaction of the amine compound and the guanylating agent to form a guanylated amine compound; (c) combining (1) the guanylated amine compound, and (2) a reactive monomer comprising (i) at least one ethylenically unsaturated group and (ii) at least one group that is reactive with an amino group; and (d) allowing or inducing reaction of the guanylated amine compound and the reactive monomer to form a guanidino-functional, free radically polymerizable compound.

  制备胍基功能自由基聚合化合物的过程包括(a)结合(1)包含(i)至少一个主链脂肪氨基团和(ii)至少一个次级链脂肪氨基团、主链芳香胺基团或次级芳香胺基团的胺基化合物和(2)胍基化试剂；(b)允许或诱导胺基化合物和胍基化试剂发生反应以形成胍基化胺基化合物；(c)结合(1)胍基化胺基化合物和(2)包含(i)至少一个乙烯不饱和基团和(ii)至少一个与氨基反应的基团的反应单体；(d)允许或诱导胍基化胺基化合物和反应单体发生反应以形成胍基功能自由基聚合化合物。
• [EN] TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY<br/>[FR] COMPOSÉS TRICYCLIQUES POUR DÉGRADER DES NÉO-SUBSTRATS POUR UNE THÉRAPIE MÉDICALE
  申请人：C4 THERAPEUTICS INC

  公开号：WO2022081927A1

  公开（公告）日：2022-04-21

  The invention provides tricyclic compounds that degrade neosubstrates for use in the treatment of disorders described herein, including, for example, abnormal cellular proliferation, neurodegenerative diseases, and autoimmune diseases.

  本发明提供了三环化合物，用于治疗本文所述的疾病，包括但不限于异常细胞增殖、神经退行性疾病和自身免疫性疾病，这些化合物可以降解新的底物。
• PROCESS FOR PREPARING GUANIDINO-FUNCTIONAL MONOMERS
  申请人：3M INNOVATIVE PROPERTIES COMPANY

  公开号：US20160096802A1

  公开（公告）日：2016-04-07

  A process for preparing guanidino-functional, free radically polymerizable compounds comprises (a) combining (1) an amine compound comprising (i) at least one primary aliphatic amino group and (ii) at least one secondary aliphatic amino group, primary aromatic amino group, or secondary aromatic amino group, and (2) a guanylating agent; (b) allowing or inducing reaction of the amine compound and the guanylating agent to form a guanylated amine compound; (c) combining (1) the guanylated amine compound, and (2) a reactive monomer comprising (i) at least one ethylenically unsaturated group and (ii) at least one group that is reactive with an amino group; and (d) allowing or inducing reaction of the guanylated amine compound and the reactive monomer to form a guanidino-functional, free radically polymerizable compound.

  制备含有胍基官能团、自由基聚合化合物的过程包括：（a）混合（1）一种胺化合物，该胺化合物包括（i）至少一个一级脂肪族氨基团和（ii）至少一个二级脂肪族氨基团、一级芳香族氨基团或二级芳香族氨基团，以及（2）一种胍基化试剂；（b）使胺化合物和胍基化试剂发生反应形成胍基化胺化合物；（c）混合（1）胍基化胺化合物和（2）一种反应单体，该反应单体包括（i）至少一个乙烯基不饱和基团和（ii）至少一个与氨基反应的基团；（d）使胍基化胺化合物和反应单体发生反应形成含有胍基官能团、自由基聚合化合物。